Company Announcement no. 14/2009
To: NASDAQ OMX Copenhagen Hørsholm, Denmark, August 12,2009
LifeCycle Pharma's Updated Financial Calendar 2009
LifeCycle Pharma A/S (OMX: LCP) issues today an updated financial calendar for -
009:
nd
August 20, 2009: Interim Report for 2
Quarter - for the period ending June 30, 2009.
(Changes from publication after end of business day on August 19, 2009
to the morning of August 20, 2009, 9:00 AM
CET due to board travelling arrangements).
rd
November 11, 2009: Interim Report for 3
Quarter - for the period ending September 30, 2009 (unchanged).
For more information, please contact:
LifeCycle Pharma A/S
Dr. Jim New Peter Schøtt Knudsen
President & CEO Head of Investor Relations
+45 70 33 33 00; jsn@lcpharma.com +45 20 55 38 17: psk@lcpharma.com
About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an
emerging specialty pharmaceutical company.
Clinical development is the core of LCP's effort to develop a
product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products
to combat certain cardiovascular diseases. As a
fully integrated company, LCP adapts new technologies on a fast
commercial timetable. LCP's unique, patented
delivery technology, MeltDose®, can improve absorption and bioavailability
- at low‐scale up costs - not only for a
broad spectrum of drugs already on the market but also for new chemical
entities. LCP has a cholesterol‐lowering
product, Fenoglide™, currently on the U.S. market and a diversified
near‐ and medium‐term pipeline with four product
candidates in clinical trials and a number of projects in
preclinical development. LCP is listed on the NASDAQ OMX
Copenhagen under the trading symbol (OMX: LCP).
For further information, please visit www.lcpharma.com.
LifeCycle Pharma A/S
Kogle Allé 4
DK‐2970 Hørsholm
CVR no. 26 52 77 67 Company Announcement no. 14/2009
